Latest Breaking News On - Roberth uhl - Page 1 : comparemela.com
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA. The Agreement, which will terminate effective October 12, 2023, g
AthensAttikírGreeceJulie-eastlandRoberth-uhlExchange-commissionEuropean-society-for-medical-oncologyNasdaqHarpoon-therapeutics-incInternational-myeloma-societyOption-agreementAnnual-meeting